Other substances

Aprotinin

A broad range serine protease inhibitor polypeptide.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

3
 Supporting references
0
 Contradictory references
4
 AI-suggested references
1
 Clinical trials

General information

Aprotinin is a bovine lung polypeptide with antifibrinolytic and anti-inflammatory properties. It acts as a broad-spectrum serine protease inhibitor (NCIt).

Aprotinin on DrugBank
Aprotinin on PubChem
Aprotinin on Wikipedia

Marketed as

TRASYLOL

 

Structure image - Aprotinin

RPDFCLEPPYXGPCKARXXRYFYNAKAGLCQXFVYGGCRAKRNNFKSAEDCMRXCGGA

Supporting references

Link Tested on Impact factor Notes Publication date
TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets
Calu-3 human airway epithelial cells Apr/15/2020
SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles
Preprint 		CaCo-2 cells

better in combination with omeprazole

 Apr/05/2020
Aprotinin Inhibits SARS-CoV-2 Replication
Protein factor In vitro 		Caco2 cells; , Calu-3 cells; primary bronchial epithelial cell air–liquid interface cultures; SARS-CoV-2 isolates SARS-CoV-2/FFM1,2,6, and 7. 4.83

Manifests SARS-CoV-2 inhibition in therapeutically achievable concentration (ca. 1 µM) in vitro. It acts at the level of viral entry inhibition and possibly also mitigates SARS-CoV-2 infection-induced downregulation of endogenous protease inhibitors.

 Oct/30/2020

AI-suggested references

Link Publication date
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
Sep/26/2020
Effect of Aprotinin and Avifavir Combination Therapy for Moderate COVID-19 Patients
Jun/27/2021
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19
Apr/05/2022
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Dec/09/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04527133 An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19 Active, not recruiting Not Applicable Jun/11/2020 Aug/31/2020
  • Alternative id - COVID-APR-01
  • Interventions - Drug: Aprotinin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Regional State Budgetary Healthcare Institution "Clinical Hospital №1", Smolensk, Russian Federation
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to elimination of SARS-CoV-2 virus|Time to CRP normalization|Time to D-dimer normalization|Time to body temperature normalization|Change in absolute neutrophil count (ANC)|Change in white blood cells (WBC)|Change of CRP|Change of D-dimer|Change in fibrinogen|Change of Quick's value|Change of international normalized ratio (INR)|Changes of lung injury on CT scan|Frequency of clinical status improvement by 2 scores in accordance with the WHO-OSCI or discharge from the hospital|Frequency of deterioration of the patients' status|Frequency of AEs and SAEs
Export (.csv)